Associated Papers
Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive Alterations.
Haugh AM et al.
Cancers, 2024
38611025 (PubMed )
Supplement: cancers-16-01347-s001.zip › cancers-2874995-supplementary.xlsx › TableS1
Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy.
Vasudevan HN et al.
Jama Network Open, 2023
37589977 (PubMed )
Supplement: jamanetwopen-e2329186-s001.xlsx › TableS1
Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy.
Fitzgerald S et al.
Molecular Diagnosis & Therapy, 2023
37099071 (PubMed )
Supplement: 40291_2023_651_MOESM1_ESM.xlsx › Suppl._Table_2
The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma.
Karachaliou GS et al.
Bmc Cancer, 2022
34986841 (PubMed )
Supplement: 12885_2021_8908_MOESM2_ESM.xlsx › APC_CTNNB1_wild_type
Functional analysis of RPS27 mutations and expression in melanoma.
Floristán A et al.
Pigment Cell & Melanoma Research, 2020
Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma.
Calapre L et al.
Molecular Oncology, 2019
30312528 (PubMed )
Supplement: MOL2-13-171-s003.xlsx › Table_S2
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Chalmers ZR et al.
Genome Medicine, 2017
28420421 (PubMed )
Supplement: 13073_2017_424_MOESM7_ESM.xlsx › Sheet1
Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma.
Prickett TD et al.
Nature Genetics, 2011
Select a paper to view details